clinical trial · NCT06926283
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.·phase1·recruiting·n = 110
Prostate CancerOther Solid TumorsEwing SarcomaDXC008
brief summary
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC008 in patients with prostate cancer and other solid tumors such as Ewing sarcoma.
started
May 15, 2025
primary completion
Apr 1, 2030
completion
Apr 1, 2030
last updated
Apr 24, 2026
official title
A Phase I, Open-Label, Multicenter, First-in-Human, Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profiles and Preliminary Efficacy of DXC008 in Patients With Prostate Cancer and Other Solid Tumors (Such as Ewing Sarcoma)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol